Zika virus (ZIKV) infection remains a public health concern with the recent epidemic infecting 30 millions of people in the Americas. Prior exposure to a single serotype of dengue virus (DENV) 31 ZIKV 12 months after DENV infection afford a high level of T cell-mediated cross protection than 87
predisposes individuals to severe disease upon secondary heterologous DENV infection. Here 32 we are showing that the length of time between DENV/ZIKV infections has a qualitative impact 33 on controlling ZIKV infection. We identified limited but significant differences in the magnitude of 34 the early humoral immune response associated to a period of twelve months but not three 35 months of DENV convalescence. However, their role limiting ZIKV replication is not conclusive. 36
There were not evidences of in vivo antibody-dependent amplification of ZIKV by previous 37 DENV immunity in any group. We also confirmed that the significant differences among groups 38 are mediated by the pre-existence of a robust effector memory T cell and cytotoxic activity 39 mainly mediated by CD4+ T cells. We demonstrated that exposure to ZIKV 12 months after 40 DENV infection afford a high level of T cell-mediated cross-protection that was not observed at 41 span of 3-months. These results suggest that there is a window of optimal cross-protection 42 between ZIKV and DENV with significant consequences. These results have pivotal implication 43 while interpreting ZIKV pathogenesis in flavivirus-experimented populations, diagnostic results 44 interpretation and vaccine designs among others. 45 such as fetal loss 1 , congenital Zika syndrome (CZS) 2 , Guillain-Barré syndrome (GBS) 3 , and 48 rare cases of encephalopathy 4 , meningoencephalitis 5 , myelitis 6 , uveitis 7 , and severe 49 thrombocytopenia 8 . Previous studies have shown that prior exposure to a single serotype of 50 dengue virus (DENV) predisposes individuals to severe disease upon secondary heterologous 51 DENV infection. However, the association of previous flavivirus exposure at any time before 52 ZIKV infection with the severe adverse outcomes of the infection is still unclear. 53 ZIKV infection remains a public health concern with the recent epidemic infecting millions of 54 people in the Americas 8 . ZIKV also poses a pandemic threat, with studies demonstrating that a 55 larger range of the tropical and subtropical regions have suitable conditions for ZIKV 56 transmission and dissemination 1 . ZIKV is mainly transmitted through the bite of Aedes aegypti, 57 the same vector implicated in DENV infection, there are however other routes of infection 58 including sexual contact 9-11 and vertical transmission 12-14 that increase the spread of the virus. 59
Diseases associated with arboviruses are cyclical. While viruses like DENV and yellow fever 60 (YFV) remain endemic in multiple areas of the world, outbreaks of increased disease severity 61 associated with these viruses occur intermittently over the course of multiple years. The timing 62 of these outbreaks is particularly relevant for DENV as the time between a primary and a 63 secondary DENV infection is relevant to the clinical presentation. A short interval between 64 homologous or heterologous DENV infection usually results in protection from disease, while an 65 extended period of time is associated with the potential for severe dengue 15-17 , due to either 66 cross-reactive antibodies 18, 19 and/or T cells 20-22 . 67 Little is known about the contribution of virus-specific and cross-reacting antibodies or the 68 cellular immune response generated by a primary DENV infection on the viremia and 69 pathogenesis of a secondary ZIKV infection in vivo 23 . To address the role of prior flavivirus 70 exposure on ZIKV-associated to disease severity we recently showed that a previous DENV 71 infection (>2 years) does not result in an increase in ZIKV viremia or pathogenesis 24 . 72
Interestingly, DENV-immune animals showed a non-statistically significant shorter viremic 73 period compared to DENV-naive macaques. 74
In this work, we examine the contribution of time between primary and heterologous flavivirus 75 exposure to determine if that factor contributes to cross-protection between ZIKV and DENV. 76 We found that the length of time between the DENV and ZIKV infections has a qualitative 77 impact on controlling the ZIKV infection. In this study, as in our prior work we did not observe 78 evidence of ZIKV disease enhancement associated with prior DENV exposure. We also 79 confirmed that the significant differences among groups are mediated by the pre-existence of a 80 robust effector memory T cell (TEM) and cytotoxic activity mainly mediated by CD4 + T cells 81 more than qualitative differences in the humoral immune response. However, by conducting a 82 detailed study of the ZIKV-neutralizing titers vs. ZIKV RNAemia at early time points after 83 infection, we were able to determine a possible contribution of the neutralizing antibodies 84 limiting the ZIKV replication at 7 days after infection in the animals with 12 months but not 3 85 months of DENV immunity or in the control group. Overall, we demonstrated that exposure to 86
Of note, DENV-middle convalescent animals had significantly lower peak viremia on day 4 139 compared with the rest of the animals (P<0.042 vs. naïve and P<0.019 vs. DENV3M group). By 140 day 5 all three groups had two animals with undetectable viremia. However, the set-point 141 viremia in the four animals from DENV-12M group was significantly lower compared to the four 142 animals having viremia in the naïve group (P<0.039) ( Fig. 3A and Table 1 ). By days 6 and 7 p.i., 143 there was no viral RNA detection in the DENV-middle convalescent group, while DENV 3M 144 animals showed a trend towards an intermittent viremia and most of the naïve animals still had 145 detectable viral RNA. By days 30 and 60 all animals tested negative for ZIKV ( Fig. 3A and Table  146 1). 147
We defined total mid-RNAemia days as the days with detectable viremia out of all possible days 148 with detectable viremia during the collection period. The animals exposed to DENV 12 months 149 earlier had the least viremia days in comparison with the naïve group, and the difference was 150 statistically significant (P<0.05) (Fig. 3B ). These results suggest that a previous infection with 151 DENV contributes to an earlier and more efficient control of ZIKV viremia in a subsequent 152 infection, but only if at least 12 months (a middle convalescence period) have passed between 153 infections. Lastly, ZIKV vRNA in urine was measured using qRTPCR, but only one animal from 154 the DENV 3M group (MA023) had detectable levels at day 6 p.i. (results not shown). 155 163 Serological profile is modified by the time between the two infections. To assess the 164 impact of previous exposure to DENV at different times in a humoral response against a 165 subsequent ZIKV infection, all sixteen animals were tested for binding antibodies against ZIKV 166 and DENV serotypes following ZIKV infection. All three groups had levels of anti-DENV IgM 167 below the cutoff value during the three collection periods, suggesting ZIKV infection did not 168 induce DENV-specific IgM response ( Fig. S3A ). As expected, all DENV immune animals had 169 detectable IgG levels against DENV at baseline ( Fig. S3B ). Anti-DENV IgG levels were 170 confirmed in both DENV-pre-exposed groups and by day 30 experimented a significant 171 expansion compared to their basal levels (P<0.05; mean diff: -0.27, CI95% -0.5145 to-0.02546 172 P< 0.005; mean diff: -0.3, CI95% -0.4997 to -0.1003 for the DENV3M and DENV12M groups 173 respectively). Those cross-reacting antibodies were also significantly higher compared to the 174 naïve animals on day 30 (P<0.0001; mean diff.: 0.96, CI95%: 0.61 to 1.30 for DENV 12M vs 175 1 2 3 4 5 6 7 3 0 6 0 T o t a l M e a n BS97 5.742 (<20) 6.298 6.071 (<20) 3.626 1.956 (40) 0.0 ( 40) 0.0 ( 80) 0.0 (5120) 0.0 (2560) slowly decreasing by day 60 p.i. (Fig. S3B ). After a limited increase of the anti-DENV IgG levels 179 on day 30 p.i. the levels rapidly decrease by day 60 in the naïve group. Moreover, by day 30 180 p.i., DENV-middle convalescent animals showed a strong trend of having higher levels of anti-181 DENV IgG compared to the DENV-early convalescent animals, although no statistical 182 significance was reached. 183
As expected, all ZIKV-infected animals developed anti-ZIKV IgM 30 days after the infection (Fig.  184 S3C). However, those antibodies were early detected only in three animals from the DENV12M 185 group with two subjects showing a peak on that day (5O8, 1O1) ( Fig. S3C ). All DENV-immune 186 animals had detectable levels of anti-ZIKV IgG at baseline compared to the naïve animals, 187 suggesting a strong cross-reactivity between previously generated anti-DENV IgG to ZIKV ( Fig.  188 S3D). DENV-early convalescent animals had significantly higher levels of anti-ZIKV IgG than 189 the other DENV-immune animals (DENV12M) at baseline (P<0.05; mean diff.: -0.59, CI95%: -190 1.15 to -0.05). By day 7 p.i., DENV-immune animals have higher levels of anti-ZIKV IgG that 191 increase throughout days 30 and 60 p.i.. Similar but slower increase was detected in the naïve 192 group. Nonetheless, all three groups showed a boost in anti-ZIKV IgG levels by day 30 p.i. with 193 a significant expansion at day 60 only in the DENV-immune animals (P<0.0001; mean diff.: -194 1.187, CI95%: -1.848 to -0.525 and P<0.0001; mean diff.: -1.176, CI95%: -1.716 to -0.636 for 195 DENV3M and DENV12M groups respectively ( Fig. S3D ). However, all animals except one in the 196 naïve group also experiment a significant expansion in their level of anti-ZIKV IgG by day 60 197 compared to day 30 (P<0.0001; mean diff.: -1.231, CI95%: -1.771 to -0.691). 198
Only one animal from the DENV-early convalescent group (MA062) had very low but detectable 199 anti-ZIKV NS1 IgG levels at baseline ( Fig. S3E ). All ZIKV-infected animals showed a boost in 200 anti-NS1 levels by day 30 p.i., with DENV-middle convalescent group having significantly higher 201 levels compared to early convalescent and naïve animals (P<0.01; mean diff.: 1.05, 202 CI95%: 0.2608 to 1.836 for DENV12M vs. DENV3M; P<0.0001; mean diff.: 2.15, CI95%: 1.45 to 203 2.859 for DENV12M vs naïve).These levels decreased by day 60 p.i., and the drop is more 204 dramatic in the pre-immune animals ( Fig. S3E ). Antibodies against ZIKV EDIII were also 205 measured in order to determine their contribution to humoral immunity and for their known 206 specific contribution to ZIKV neutralization 25( Fig. S3F ). Only one animal from the DENV-middle 207 convalescent group showed detectable levels of anti-ZIKV EDIII before ZIKV infection. Anti-208 ZIKV EDIII levels for all groups slowly increased throughout 30 and 60 days p.i., and the 209 increase at day 60 p.i. was significant for DENV-immune animals with respect to their basal 210 levels (P<0.05; mean diff.: -0.85, CI95%: -1.68 to -0.03 for DENV12M animals, and P<0.001; 211 mean diff.: -1.26, CI95%: -2.27 to -0.25 for DENV3M animals). No significant differences were 212 observed among the groups, suggesting that previous exposure to DENV does not have an 213 impact on the generation of cross-reactive antibodies against ZIKV EDIII epitopes and that 214 these antibodies may have limited contribution to ZIKV neutralization. 215
Only one animal from the DENV-early convalescent group (MA062) had very low but detectable 216 anti-ZIKV NS1 IgG levels at baseline ( Fig. S3E ). All ZIKV-infected animals showed a boost in 217 anti-NS1 levels by day 30 p.i., with DENV-middle convalescent group having significantly higher 218 levels compared to early convalescent and naïve animals (P<0.01; mean diff.: 1.05, CI95%: 219 0.2608 to 1.836 for DENV12M vs. DENV3M; P<0.0001; mean diff.: 2.15, CI95%: 1.45 to 2.859 220 for DENV12M vs naïve). These levels decreased by day 60 p.i., and the drop is more dramatic 221 in the pre-immune animals ( Fig. S3E ). Antibodies against ZIKV EDIII were also measured in 222 order to determine their contribution to humoral immunity and for their known specific 223 contribution to ZIKV neutralization 25 ( Fig. S3F ). Only one animal from the DENV-middle 224 convalescent group showed detectable levels of anti-ZIKV EDIII before ZIKV infection. Anti-225 ZIKV EDIII levels for all groups slowly increased throughout 30 and 60 days p.i., but no 226 significant differences were observed among the groups, suggesting that previous exposure to 227 DENV does not have an impact on the generation of cross-reactive antibodies against ZIKV 228 EDIII epitopes and that these antibodies may have limited contribution to ZIKV neutralization. 229 230
The time between DENV/ZIKV infections modifies the neutralizing profile. 231
To determine the contribution of binding antibodies to the neutralization and the impact of a 232 previous DENV infection in a subsequent ZIKV infection in terms of neutralization potential, all 233 three groups were tested using PRNT and FRNT assays against ZIKV and the four DENV 234 serotypes respectively. Neutralization assays were completed for baseline, days 30 and 60 for 235 DENV and ZIKV. To better understand if the previous DENV immunity plays a role in the 236 neutralization of ZIKV, we also ran PRNT assay for days 3, 5, 6 and 7. The endpoint titers are 237 showed in Table 1 along with the viremia set point values in order to facilitate a better 238 interpretation of the relationship between both parameters.
In figure 4 the 50% effective concentration (EC) of neutralizing antibodies is shown. As 240 expected, all three groups had low or absent neutralizing antibodies against ZIKV at baseline 241 ( Fig. 4A ). As early as 6 days after the infection an increase in the neutralizing activity against 242 ZIKV is detected in all groups with a slight non-significant trend to be higher in the DENV12M 243 group. This increase continues on day 7 with the trend to be higher in both preimmunized 244 groups. By day 30 p.i., neutralizing titers had boosted in the three groups, with DENV-middle 245 convalescent animals showing a slight trend towards higher levels of dilution effective for half-246 maximum neutralization compared to DENV3M and naïve groups. These levels decline slightly 247 by day 60 p.i but still maintained a similar trend among groups (Fig. 4A ). In order to expand our 248 analysis of the contribution of the humoral immune response to the early viral replication we 249 further looked at the dilution:neutralization capacity relation in samples from all timepoints. As 250 shown in figure 4C , we identified significant differences, at the highest serum concentrations in 251 the magnitude of the neutralization (only dilutions showing more than 60% of neutralization were 252 considered) on days 6 (P<0.001 and P<0.029 for DENV12M and DENV3M vs. naïve 253 respectively at 1:20 dilution and P=0.0005 and P<0.0001 for DENV12M vs. DENV3M and naïve 254 respectively at 1:40 dilution) and 7 (P<0.0039 and P<0.0001 for DENV-12M vs. naïve at 1:20 255 and 1:40 dilutions respectively) p.i.. However, the role of the neutralization limiting viral 256 replication, particularly at day 6 after the infection, is debatable when the relationship between 257
RNAemia and end point neutralizing titers are analyzed together (Table 1) . 258
Both DENV immune groups had high levels of neutralizing antibodies against DENV2 at 259 baseline, which boosted significantly for DENV12M animals at day 30 p.i. compared to the naïve 260 group (Fig. 4B ). By day 60 p.i., these neutralizing antibodies did not decline in neither of the 261 DENV immune groups, and a significant difference was still present for DENV-middle 262 convalescent animals, which suggests that ZIKV infection induced a boost in cross-neutralizing 263 antibodies to DENV and the magnitude of the boost depend on the time elapse between DENV 264 and ZIKV infection (P=0.0006 for day 30 p.i. and P=0.02 for day 60 p.i.). Only one naïve animal 265 produced low level of neutralizing antibodies against DENV2 by day 30 p.i. that declined by day 266 60 p.i. (Fig. 4B ). Using the anti-ZIKV IgG data presented on the previous section ( Fig. S3D ), we 267 can conclude that the expansion 60 days p.i. is supported in cross-reactive non-neutralizing 268 antibodies ( Fig. 4 ). Detailed dilution end points for each animal are shown in Figure S4 When evaluating the neutralizing titers against the all four DENV serotypes, we observed a 271 boost in neutralization against all serotypes in all three groups, suggesting that a subsequent 272
Interestingly 30 days after ZIKV infection there was a non-significant trend to higher neutralizing 274 titers against DENV2 and DENV4 compared to the other two DENV serotypes in the DENV 275 naive group. The hierarchy of neutralizing antibodies generated 30 days p.i. was the same for 276 both DENV immune groups (D2>ZIKV>D4>D3>D1), and for the naïve group it was 277 ZIKV>D4>D2>D3>D1 (Fig. S5B) . In order to determine if there were any strain-specific 278 neutralization differences, neutralization assays were performed at 30 days p.i. against two 279 recently circulating contemporary ZIKV strains, ZIKVH/PF/2013 and ZIKVPRVABC-59. As 280 showed in figure S5C, no differences in the neutralization magnitude were seen for any group. 281
Altogether, these results confirm the contribution of pre-existing DENV immunity to the 282 expansion of cross-reactive anti-ZIKV IgG levels and of the DENV cross-neutralizing antibodies 283 early after ZIKV infection in macaques. 284
Immune cell subsets frequency is shaped by previous DENV exposure. To establish how 285
previous immunity to DENV shapes the cellular response against a subsequent ZIKV infection, 286 an analysis of the involved cells was performed. Animals exposed to DENV three months earlier 287 had significantly higher frequency of B cells (CD20+) 24 hours before ZIKV infection compared 288 to the other groups (P<0.05; mean diff.: -12.33, CI95%: -22.69 to -1.979 for DENV3M versus 289 DENV12M, and P<0.01; mean diff.: 14.77, CI95%: 4.41 to 25.12 for DENV3M versus naïve 290 group). No other differences between groups were detected, although the trend observed in day 291 0 is maintained through day 3 ( Fig. S6A ). On the other hand, the frequency of activated B cells 292 (CD20+CD69+) was very similar in al three groups (Fig. S6B ). 293 While no statistical differences were observed in the activation of CD4+ or CD8+ T cells among 294 the three groups or compared to their basal levels, DENV-middle convalescent animals had a 295 lower activation of T cells on day 1 p.i., and reached a peak on day 2 p.i., which decreased by 296 day 3 p.i. (results not shown). In addition, we characterized the CD4+ and CD8+ T cells central 297 memory (TCM) and effector memory (TEM) subsets in order to determine how a previous DENV 298 infection impacts the differentiation to these compartments. The frequency of TCM CD4+ cells 299 (CD4+CD3+CD28+CD95+) was significantly lower for the DENV-middle convalescent group 300 compared to the DENV-early convalescent and naive groups at baseline (P<0.05; mean diff.: -301 19.39, CI95%: -33.23 to -5.35 versus DENV 3M and P<0.05; mean diff.: -19.5, CI95%: -31.97 to 302 -7.03 versus naïve), day 1 p.i. (P<0.05; mean diff.: -14.53, CI95%: -28.47 to -0.59 versus DENV 303 3M and P<0.05; mean diff.: -1.77, CI95%: -14.23 to 10.7 versus naïve) and day 3 p.i. (P<0.05; 304 mean diff.: -22.97, CI95%: -36.9 to -9.03 versus DENV 3M, and P<0.05; mean diff.: -17.22, 305 CI95%: -29.68 to -4.75 versus naive) ( Fig. 5A ). On the other hand, the frequency of TEM CD4+ 306 cells (CD4+CD3+CD28-CD95+) was increased and remained steady throughout the four 307 timepoints for the DENV-middle convalescent animals, in comparison with the other two groups. 308
Referring to the CD8+ TCM and TEM cells, a similar trend can be observed, although it only 309 reaches statistical significance at day 3 p.i. for TCM cells (P<0.05; mean diff.: -9.85, CI95%: -310 17.02 to -2.68 versus naïve animals), and at day 1 p.i. for TEM cells (P<0.05; mean diff.: 19.57, 311 CI95%: 0.09 to 39.04 versus DENV 3M animals) ( Fig. 5B ). Additionally, naïve animals had 312 significantly higher levels of TCM CD8+ cells compared to the DENV immune groups at 313 baseline (P<0.05; mean diff.: -15.47, CI95%: -22.63 to -8.30). 314
We noticed a trend that is especially prominent in DENV-middle convalescent animals, of higher 315 TEM cell and lower TCM cell frequencies. In order to scrutinize this pattern, we analyzed the 316 pattern of frequency in each group separately ( Fig. 5C ,D). Compared to their baseline values, 317 only naïve animals had significant differences on days 1 through 3 p.i. between CD4+ and 318 CD8+ TEM and TCM subsets (P<0.05). Additionally, the naïve animals go through a sudden 319 contraction of TCM CD4+ and CD8+ cells at day 1 p.i. that slowly begins increasing by day 3 p.i. 320 (P<0.05). Similarly, the TEM CD4+ and CD8+ cells expand, although TCM cells reach parallel 321 levels by day 3 p.i. (P<0.05). This phenomenon can be seen in DENV 3M animals in the TCM 322 CD8+ cells during day 1 p.i., but not TCM CD4+ cells. DENV 12M animals go through the same 323 occurrence, but reaching statistical difference in all three days p.i (P<0.05) ( Fig. 5C,D) . 324
Interestingly, this contraction of TCM cells and expansion of TEM cells does not translate to a 325
more efficient viremia control in the naïve or DENV 3M groups, but it does in the DENV 12M 326 group. DENV-early convalescent group had significantly lower proliferation levels of CD4+ TCM 327 cells at day 2 p.i. compared to the other two groups (Fig. S7A ). There were no other significant 328 variations observed in terms of proliferation ( Fig. S7A-D) . In contrast, same group of animals 329 had the highest activation levels of CD4+ and CD8+ TCM and TEM cells in comparison with the 330 other two groups, although no statistical differences were found ( Fig. S7E-H) . Lastly, the 331 suggested displacement from a central to an effector subset in the naïve and DENV-middle 332 convalescent groups was confirmed by the pattern showed by individual animals (Fig. S8) . 333 DENV-middle convalescent animals had a more pronounced TEM cell expansion and TCM cell 334 contraction compared to their DENV-early convalescent counterparts ( Fig. S8 ). Interesting, the 335 differences between both T cells compartments were still significant by day 3 only in the 336 DENV12M group. That higher frequency of CD4+ TEM cells in this group is associated to better 337 viremia control ( Fig S9) suggesting that the time lapse between DENV and ZIKV infections 338 shapes the ZIKV-induced cellular response. 339
T cell immune response is boosted by the time lapse between DENV/ZIKV infections.
To 341 assess if a previous DENV infection has an impact on the T cell response to a ZIKV infection, 342 their effector responses were measured. CD4+ and CD8+ T cells produced IFNg, TNFa, and 343
CD107a in response to various stimuli ( Fig. 6A-B ). The IFNg response in the CD4+ T cells from 344 the DENV 12M group before ZIKV infection is remarkable. The frequency of these cells was 345 significantly higher in response to the whole inactivated DENV (P<0.05) and showed a strong 346 trend to have a higher frequency of IFNg producing cells in response to peptides derived from 347 the DENV and ZIKV envelopes and ZIKV non-structural proteins as well. Pro-inflammatory cytokines are not exacerbated by previous DENV immunity. We wished 360 to determine how DENV immunity impacts the cytokine secretion during a subsequent ZIKV 361 infection ( Fig. 7) . Naïve macaques had significantly higher levels of pro-inflammatory cytokine 362
IFNa on day 1 p.i. compared to the other groups (P<0.05; mean diff.: -145.6, CI95%: -271.7 to -363 19.37) ( Fig. 7A ). This trend continued through the rest of the collection period, but no other 364 significant differences were detected. DENV 12M animals had seemingly higher levels 365 compared to their DENV 3M counterparts, although no statistical significance was reached. A 366 similar event can be observed with CXCL10, where naïve animals had a significant boost by 367 day 1 p.i. in comparison with the other two DENV-immune groups, although a dramatic drop 368 occurs on the following 24 hrs (P<0.05; mean diff.: -533, CI95%: -22.69 to -1.98) ( Fig. 7B ). On 369 day 2 the levels of CXCL10 increase prominently on the DENV immune animals, noticeably 370 higher and more consistent on the DENV 12M group, but no significant differences are noted. 371
This same group of DENV-middle convalescent animals showed a trend towards higher MIP-1a 372 levels, reaching significant differences in day 5 and 7 p.i. (P<0.01), while naïve animals showed 373 an increase in MIP-1b levels by day 1 p.i. (P<0.01), followed by a sudden drop ( Fig. 7C and D, 374 respectively). Likewise, an increase in IL-1Ra levels, which is considered an inflammatory 375 marker, was detected in naïve animals at day 1 p.i. that is significantly higher than levels in 376 DENV-immune animals (P<0.01; mean diff.: -1723, CI95%: -3060 to -385.1 versus DENV 12M; 377 P<0.01; mean diff.: -1809, CI95%: -3305 to -313.18 versus DENV 3M), but it decreases in the 378 next 24 hours ( Fig. 7E ). On the other hand, a significant increase in BAFF levels at day 5 p.i. 379 was observed in DENV 12M animals (P<0.05; mean diff.: -3044, CI95%: -5999 to -87.73) ( Fig.  380 7F). Interestingly, animals exposed to DENV 12 months before ZIKV infection showed higher 381 levels of circulating perforin, reaching a significant difference compared to the other two groups data presents no detectable differences in the frequency of dendritic cells of pDC lineage or 389 absolute pDCs between groups (results not shown). In contrast, dendritic cells of myelocytoid 390 lineage (mDCs) show a significant increase in frequency at days 1 and 2 p.i. in DENV 12M 391 animals (P<0.01; mean diff.: 10.54, CI95%: -2.65 to 18.43 for DENV 12M versus naïve animals 392 on day 1 p.i.; for day 2 p.i., P<0.01; mean diff.: 13.68, CI95%: 4.87 to 22.50 for DENV 12M 393 versus DENV 3M and, P<0.0001; mean diff.: 15.57, CI95%: 7.68 to 23.45 for DENV 12M versus 394 naïve animals)( Fig. S11 ). This suggests that an early activation of mDCs induced by previous 395 immunity to DENV correlates with ZIKV control. This result is coherent with previous finding that 396 CXCL10 ( Fig. 7B ) frequency was higher in DENV immune animals after day 2 p.i., especially in 397 those exposed to DENV 12 months before, supporting control of viremia in this group. 398
Discussion 400
It is well established that exposure to DENV prior to a ZIKV infection results in a qualitative 401 modification of the humoral and cellular immune response to ZIKV in mice, macaques and 402 humans 24,26-29 . However, we know from early human temporal challenge studies with multiple 403 serotypes of DENV that the timing between flavivirus exposure can alter the balance between 404 heterologous immune pathogenesis and protection. In human populations living in flavivirus 405 endemic areas, it is difficult to establish the exact time of a primary infection and more difficult 406 to establish the time between two consecutive infections. 407
Macaques provide a robust model to study the immunological profile after sequential flavivirus 408 infections 24,30,31 . Using the macaque model allows among other factors, to normalize the 409 quantity of viral inoculum, the age, and sex of the animals exposed, and the timing of the It is well documented that secondary flavivirus infections, including ZIKV, lead to an increase in 428 cross-reactive Abs and nAbs 28,35-37 . We found a transient but significant expansion in the 429 magnitude of the DENV cross-reactive Abs in the pre-immune groups 30 days after ZIKV 430 infection with a rapid decline by day 60. We also confirmed the preexistence of cross-reacting 431 but non-neutralizing antibodies to ZIKV in the DENV-immune groups 35, 36 . However, those 432 antibodies were significantly higher only in the DENV-early convalescent group compared to the 433 middle convalescent group. This confirms the high frequency of ZIKV cross-reacting antibodies 434 during the early DENV convalescence that wane during the middle and late convalescent 435 periods 35, 37 . Similarly, the levels of the antibodies to NS1 was significantly higher in the group 436 with a middle convalescent period to DENV compared to the other two groups suggesting the 437 presence of more mature memory B cells in this group in comparison with the other DENV 438 immune group. Cumulatively from our previous results 24 and this current work, we can conclude 439 that the neutralization against ZIKV is very limited or absent in all samples we tested after 440 DENV and before ZIKV infections, regardless of the convalescence status. Our results are in 441 agreement with recent findings by Montoya et al. 37 and in partial agreement with other reports 442 using human samples 35, [38] [39] [40] . The discordance may be related to the differences in the definition 443 of the convalescencece period in those previous works. 444
Taking advantage of our model we completed a detailed analysis between the nAbs and the 445
RNAemia within the first week of ZIKV infection that otherwise would be difficult to conduct in 446 humans' cohorts. While we identified a significant decline in the viremia set-point on day four in 447 the DENV-12M group only, starting from day 5 to 7 we characterized a limited increase in the 448 magnitude of ZIKV neutralization activity in the DENV12M group. That early increase was 449 characterized by the presence of low-to-intermediate levels of neutralizing antibodies but no 450 correlation can be made with the viremia on days 5 and 6. However, by day 7, only in the 451 animals with DENV-middle convalescence immunity a consistent increase in the ZIKV 452 neutralizing antibodies correlating with the absence of RNAemia was observed only in the 453 animals with DENV-middle convalescent immunity. This result suggests that the humoral 454 immune response in subjects with previous DENV-immunity may contribute to controlling ZIKV 455 replication around one week after the infection. However, the time elapsed between the DENV 456 and ZIKV exposures seems to be a critical factor for that contribution. 457
As we discuss below, other mechanisms, most likely associated with the preexisting DENV- responsible for generating long-lived, high-affinity Antibody Secreting Cells (ASC) that in turn 467 are able to generate a better-quality response against re-infections 45 . Interestingly, our results 468
show a significant increase in BAFF level (a key factor in germinal center maintenance, B cell 469 maturation, and antibody production) at day five for the animals exposed to DENV 12 months 470 earlier, suggesting a GC response involvement. . In this study, we are able to combine our previous insights into the role of TCM and TEM 498 cells on prior heterologous flavivirus infection 24 to our current work on the temporal boundaries 499 of immune protection from a heterologous flavivirus infection. From our work, the role of the 500 cellular immune response in facilitating the initial significant decrease of ZIKV replication 501 between days 4 to 7 is very likely. The group challenged with ZIKV 12 months post-DENV 502 infection was better at controlling ZIKV viremia, together with lower levels of the liver enzyme 503 AST compared to the naïve group. Additionally, that group showed a significantly higher 504 frequency of pre-existing TEM CD4+CD3+CD28-CD95+ cells prior to and present until day 3 505
(the last time point tested) after ZIKV infection. Particularly relevant is the significant preexistent 506 combination of high TEM and lower TCM cell frequencies in the group exposed to DENV 12 507 month prior to ZIKV infection. 508
A limited but statistically significant proliferation of the CD4+ TCM cells was noted two days 509 after the infection only in the naïve and 12M DENV-immune groups compared to the 3M DENV-510 immune group. However, proliferating CD4+ and CD8+ T-cells have been reported by 6-8 days 511 post-ZIKV infection 30,48,49 . Unfortunately, as a consequence of the devastating impact of 512 hurricane Maria, we were unable to collect samples from day 7 until day 30 p.i. in our cohorts. 513
However, from the time points we were able to analyze after ZIKV infection we detected a 514 contraction of the TCM and an expansion of the TEM respectively in naive animals for both the 515 CD4+ and CD8+ T cells compartments, indicating that the changes in magnitude in those types 516 of cells were specific for ZIKV infection. Of note, the expansion and the contraction of the CD4+ 517 TEM and TCM respectively, were significant compared to their baseline values only in the naïve 518 groups but was insufficient for effective control ZIKV viremia or to limit the hepatic insult. 519
A ZIKV-dependent displacement of the central to the effector memory cells was also confirmed 520 by the fact that most animals with lower frequencies of TCM cells showed a higher frequency of 521 TEM cells. Notably, in our study the animals with the early convalescent period to DENV prior to 522 ZIKV infection showed a significantly lower frequency of CD4+ TEM cells compared to the 523 demonstrates that the frequency of CD107a+ CD4+T cells from DENV immune NHPs correlates 549 with enhanced protection from ZIKV challenge. CTL activity of the CD4+T cells, as determined 550 by the expression of the degranulation marker CD107a, showed higher frequency and 551 magnitude in the 12 months DENV immune animals compared to the naïve group. We also 552 noted that DENV specific CD4+T cells isolated one year after DENV infection was highly 553 responsive to the whole DENV virus prior to ZIKV infection (characterized by a significantly 554 higher frequency of IFN-g production and CD107a expression) and following ZIKV infection the 555 focus CD4+T cells was to ZIKV envelope and non-structural antigens 30 days after ZIKV 556 infection. That switch was a trend, but not significant in animals with an early period of 557 convalescence to DENV. Interesting it has been shown that a higher frequency of DENV-558 specific IFN-g producing T cells are associated with subclinical manifestations in children 559
suffering from secondary DENV infection 59 . Our finding on CD4 T cells is consistent with a 560 previous report confirming that preexisting memory CD4 T cells (and not the CD8 T cells or 561 antibodies) are responsible for limiting the severity of illness caused by influenza 60 . Notably, the 562 data for CD8+T cells did not recapitulate the observations of the CD4+ T cells. We noted 563 relatively similar responses between the CD8+T cells isolated from the 12M DENV immune 564 compared to the 3M DENV immune animals. This suggests that the CD4+T cell response 565 changed over time leading to potential differences in disease. 566
The immunopathogenesis of liver damage induced by DENV infection has been addressed in 567 human and animal models, but very limited data is available for ZIKV infection or for sequential 568 DENV with a group of 22 subjects with severe dengue, the increase of AST, GGT and ALT 575 peaked up by day 6-7 and did not associate with the degree of viremia or the onset or extent of 576 fluid leakage. They found that the liver damage was more related to a possible immune 577 mechanism and associated to higher levels of IL-10 and IL-17 62 . Results from mice also confirm 578 that liver damage is associated with higher systemic levels of proinflammatory cytokines, 579
including TNF-alpha and IL-17, and not to DENV replication 63,66 . In fact, Martinez-Gomez et al 580 showed that anti-TNF-alpha reduce the liver damage significantly without any impact in the 581 viremia 66 . Particularly relevant is the limited elevation of the AST in both DENV-immune groups 582 compared to the naïve animals and the increase of that enzyme in 5 of 6 naïve animals 6 days 583 p.i. above the normal ranges. That enzyme (AST) has been reported more frequently elevated 584 and at higher levels than ALT in humans with DENV-induced liver damage 62,70-73 . We found a 585 limited proinflammatory cytokine profile in the naïve animals that may explain the significant 586 increase of liver enzymes in that group. On the other hand, we hypothesize that the limited 587 elevation of liver enzymes in the 3M group at early time point after ZIKV infection is in 588 agreement with the limited immune activation we are reporting in the first days after infection in 589 that group, most likely due to the short period of time between consecutive DENV/ZIKV 590
infections. 591
The significant role of the T cells in controlling ZIKV replication and as consequence limiting the 592 liver damage in the animals with a DENV-middle convalescence period before ZIKV infection is 593 reinforced by the significant increase of circulating cytolytic protein perforin at day 7 p.i.. We hypothesize that this likely represents T cells acquisition of cytotoxic function 74 in that group 595 compared to the other two groups and correlates with the higher expression of CD107a on the 596 CD4+T cells isolated from the middle convalescent animals. Previously we confirmed a peak in 597 perforin levels in the serum 6 days after ZIKV infection in animals with 2.8 years of previous 598 immunity to DENV 24 . Others have shown that Granzyme B levels in CD4+ and CD8+ T cells 599 peaked between 7 and 10 days post-ZIKV infection 49 . 600
The protective role of the cellular immune response controlling the viral burden of ZIKV in mice 601 has been reported 75, 76 . More recently mouse models have shown that prior DENV immunity can 602 protect against ZIKV infection during pregnancy, and CD8+ T cells are sufficient for this cross-603 protection 77 . Currently, it is well documented that pre-exposure to DENV both in macaques and 604 humans results in a qualitative modification of the humoral and cellular immune response to 605 ZIKV 24,27-29 .
606
The uniqueness of our report is that we provide evidence that the magnitude and the breadth of 607 flavivirus immunity depends not only on pre-infection immune status but time between 608 exposures, with significantly different protection outcomes. Also, taking advantage of the NHP 609 model, we are providing a dissection of the early events of the protective immune response. We 610 are providing mechanistic evidence of the early role of cellular immunity in such protection and 611 characterized a window of transition to the contribution of the humoral immune response. 612
We are showing that in the presence of previous DENV infection, the increase in the frequency 613 of the specific TEM cells and of the cytotoxic CD4+ T cells and in the magnitude of ZIKV 614 neutralization may occur at any time after ZIKV infection. However, playing a significant role 615 controlling ZIKV viremia and liver damage happens only after a middle-convalescent period of 616 approximately 12 months, but not too early (3 months) or too late (2.8 years) after the primary 617 DENV infection. Interestingly a recent report showed that the IgG3 levels (a marker of recent 618 DENV infection) were positively associated with risk of infection by ZIKV 34 . In humans, this fact 619 correlates with our finding in NHPs that a shorter period of DENV immunity may not provide a 620 protection against ZIKV. From our results we cannot anticipate if the effect of previous DENV 621 immunity or the time between DENV and ZIKV infection may have any implications during the 622 pregnancy. More complex studies using a large number of NHPs and well controlled 623 prospective studies in human populations are needed to elucidate such a relationship 78 . Our was used in order to compare results to our previously published data. This ZIKV strain 632 replicates well in rhesus macaques but has a lower viremia peak than ZIKV H/PF/2013 strain. 633
We aimed to use a strain from the recent epidemic in the Americas region. Virus was expanded 634 and titered by plaque assay and qRT-PCR using protocols standardized in our laboratories. virus diluted in PBS, using a dose of 1 x 10 6 pfu. All macaques were male. The average age for 660 cohort 1 was 5.1 years (5.6, 4.9, 5.1, 4.9, 5.0 and 5.0 years), 6.8 years for cohort 2 (5.5, 7.75, 661 antibody (Sigma), diluted 1:1,000 in blocking buffer. Foci were developed with TrueBlue HRP 694 substrate (KPL) and counted. For the Focus/Plaque Reduction Neutralization Test 695 (FRNT/PRNT), sera were diluted two-fold and mixed with approx. 35 foci per plaque-forming 696 units (FFU per p.f.u. per mL) of virus and then incubated for 1hr/37C/5%CO2/rocking. Virus-697 serum dilutions were added to 24 well-plates containing Vero81 cells as mentioned above, and 698 incubation was continued for 1hr/37C/5%CO2/rocking. After incubation, overlay was added, and 699 the aforementioned procedure was repeated. Mean focus diameter was calculated from approx. Diagnostics, CA). After ZIKV infection, seroreactivity to DENV was tested using commercial IgG 720 and IgM ELISA kits (Focus Diagnostics, Cypress, CA). ZIKV IgG was assessed with available 721 commercial kits (XpressBio, Frederick, MD and InBios, Seattle, WA respectively). ZIKV-NS1 722
IgG was examined using a commercial kit (Alpha Diagnostic, San Antonio, TX). All tests were 723 performed per the manufacturer's instructions. For the measurement of IgM levels against ZIKV, 724 samples were tested using a ZIKV IgM MAC-ELISA assay developed by Aravinda de Silva's 725 laboratory. Briefly, a 96-well microtiter plate was coated with anti-human IgM (1:50). The plate 726 was left at 4 C° overnight. Following incubation, coating was removed by dumping and the plate 727 was blocked for 30 minutes at room temperature. After blocking, the plate was washed once, 728 and sample dilutions were prepared (1:40) and added to the plate. Positive and negative 729 controls for ZIKV and DENV were also prepared. After the addition of samples and controls, the 730 plate was incubated one hour at 37 C° in a humidified chamber. Before adding the antigens, the 731 plate was washed twice. Stock C6/36 ZIKV and DENV antigens were diluted (1:2 and 1:3, 732 respectively), and added to the plate. The plate was incubated overnight at 4 C° in a humidified 733 chamber. The next day, the plate was washed twice, and a horseradish peroxidase (HRP)-734 conjugated monoclonal antibody (6B6C-1) was added, followed by incubation for one hour at 37 735 C° in a humidified chamber. Detecting antibody was diluted in blocking buffer 1:1000 prior to 736 addition to plate. A last cycle of washing (twice) was performed, and TMB substrate was added 737 to all wells. Plate was covered immediately to block out light and incubated at room temperature 738 for 30 minutes. Before colorimetric detection, the plate was allowed to sit at room temperature 739 for 5 minutes. Optical density at 450 nm (OD) values were measured in three separate readings 740 CD11c-PE/Cy7 (3.9), CD8-FITC (SK1) and CD8-BV421 (SK1) from Biolegend. For analyses, 757 LYM were gated based on their characteristic forward and side scatter pattern; T cells were then 758 selected with a second gate on the CD3 positive population. CD8+ T cells were defined as 759 CD8 + CD3 + and CD4+ T cells were CD4 + CD3 + . Natural Killer cells were defined as CD3 -CD20 -760 CD14and analyzed by the expression of NK cell markers CD16, CD8, NKG2A, NKG2C, NKp30 761 and NKp46. B cells were defined as CD20 + CD3 -CD14 -. Activation marker CD69 was determined 762 in each different lymphoid cell population. Monocytes were defined as CD20 -CD3 -CD14 + and 763 CD20 -CD3 -CD14 + CD16 + . Finally, dendritic cells (DCs) were separated into two populations by 764 the expression of CD123 (pDCs) or CD11c (mDCs) in the HLA -DR + CD3 -CD14 -CD20 -765 population. Data analysis was performed using Flowjo (Treesar). PBMCs were infected overnight with DENV-2 (NGC44) at a MOI of 0.1 or ZIKV at a MOI of 0.5 771 in RPMI medium with 5% FBS. The remaining PBMCs were rested overnight as described 772 earlier in 5ml of RPMI with 10% FBS. These PBMCs were then stimulated for 6 h at 773 37C/5%/CO2 with ZIKV-E peptides (15-mers overlapping by 10 amino acids, 2.5 ug/ml -1 per 774 peptide), ZIKV-NS1 protein peptides (15-mers overlapping by 10 amino acids, 475 ng/ml -1 per 775 peptide), or DENV-2 E peptides (1.25 ug/ml -1 ), all in the presence of brefeldin A (10 ug/ml -1 ), a-776
CD107a-FITC (H4A3) (10 ul), and co-stimulated with a-CD28.2 (1 ug/ml -1 ) and a-CD49d (1 777 ug/ml -1 ). After stimulation, the cells were stained for the following markers: CD4-PerCP Cy5.5 778 (Leu-3A (SK3), CD8b-Texas Red (2ST8.5H7), CD3-PacBlue (SP34), CD20-BV605 (2H7), 779 CD95-V510 (DX2), CD28.2-PE-Cy5, IFN-g-APC (B27) and TNF-a-PE-Cy7 (MAB11). The 780 samples were run on an LSRII (BD) and analyzed using Flowjo (Treesar). Lymphocytes were 781 gated based on their characteristic forward and side scatter pattern, T cells were selected with a 782 second gate on the CD3-positive population, and at the same time CD20 positive cells were 783 excluded. CD8+ T cells were defined as CD3 + CD20 -CD8 + and CD4+ T cells as CD3 + CD20 -784 CD4 + . Cytokine expression was determined by the per cent CD4+ or CD8+ positive cells, and 785 then stained positive for the cytokine IFN-g or TNF-a. CD107a were also measured in these 786 populations to determine functional cytotoxicity. Further analysis was also performed to examine 787 Two cohorts of rhesus macaques (Macaca mulatta) were exposed to DENV-2 (5 x 10 5 pfu s.c.) at different timepoints. Both cohorts were exposed to ZIKV strain PRABCV59 (1 x 10 6 pfu s.c.) on September 12 th , 2017, along with a third cohort composed of zika and dengue naïve animals (n=6). ZIKV infection was performed 12 months after DENV infection for cohort 1 (n=6), and 3 months after DENV infection for cohort 2 (n=4). Serum was collected at baseline and days 1 through 7 post ZIKV infection (p.i.). Sample collection was interrupted by Hurricane María's impact, and resumed on day 30 p.i. PBMCs could only be obtained on baseline, day 30 and 60 p.i., while heparinized whole blood was collected on baseline and days 1 through 3 p.i. Additionally, urine was collected on baseline and days 2, 4 and 6 p.i. 2 . Vital signs and clinical laboratory status of macaques before and after ZIKV infection. Significant changes in the vital signs and laboratory values after ZIKV infection are showed. In all panels, animals exposed to DENV 12 months before ZIKV infection are depicted in blue, while animals exposed to DENV 3 months before are in orange. Naïve animals are in black. (A) External temperature (in Celsius) and (B) rectal temperature (in Celsius) were measured. Statistically significant differences among groups were calculated by two-way ANOVA using Tukey's multiple comparisons test (***P<0.0005 and ****P<0.0001). (C) Aspartate Aminotransferase (AST) and (D) Alanine Aminotransferase (ALT) levels at different timepoints. Dotted lines represent normal clinical ranges for rhesus macaques. Statistically significant differences among groups were calculated using an unpaired multiple t test, while differences within cohorts in respect with their baseline values were computed by two-way ANOVA using Dunnett's multiple comparisons test (*P<0.05, **P<0.001, ***P≤0.0001 and ****P<0.0001). Colored stars represent a significantly different group, while colored lines represent the group that it is compared to. In all panels, animals exposed to DENV 12 months before ZIKV infection are in blue, while animals exposed to DENV 3 months before are in orange. Naïve animals are in black. (A) Zika RNAemia was defined as early RNAemia (days 1 to 3 p.i.), mid RNAemia (days 4 to 7 p.i.), and late RNAemia (days 7 p.i. onwards). ZIKV replication was detected in serum during the first 7 days after infection. Statistically significant differences were observed using unpaired multiple t tests (*P<0.05). Genome copies per mL are shown logarithmically. (B) Total mid-RNAemia days were calculated using the following formula: total viremia days divided by total possible viremia days and are expressed as percentage. The obtained values were placed in a contingency table. Statistically significant differences of viremia days were calculated using a two-sided Fisher's exact test (*P<0.05). Colored stars represent a significantly different group, while colored lines represent the group that it is compared to.
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Figure 4. Geometric mean titers of dengue and ZIKV neutralizing antibodies.
The 50% effective concentration of neutralizing antibodies was determined. Animals from cohort 1 are shown in blue, animals from cohort 2 are shown in orange and naïve animals from cohort 3 are shown in black in all panels. Dotted line indicates the limit of detection for the assay. Non-neutralizing sera were assigned a value of one-half of the limit of detection for visualization and calculation of the geometric means and confidence intervals. (A) EC50 values of neutralizing antibodies against ZIKV after ZIKV infection. (B) EC50 values of neutralizing antibodies against DENV2 after ZIKV infection. Statistically significant differences among groups were calculated by two-way ANOVA using Tukey's multiple comparisons test (*P<0.05 and ***P≤0.001). (C) Dilution titers against ZIKV are shown during day 6 and 7 post ZIKV infection. Statistically significant differences among groups were calculated by two-way ANOVA using Tukey's multiple comparisons test (*P<0.05, **P<0.001, ***P≤0.001 and ****P<0.0001). Colored stars represent a significantly different group, while colored lines represent the group that it is compared to.
Figure 5. Dynamic and relationship of the central and effector memory cells in the CD4 + and CD8 + T compartments.
Changes in the level of and in the relationship between the central and effector memory cells are modified by the time passed after a previous DENV immunity. In all panels, animals exposed to DENV 12 months before ZIKV infection are in blue, while animals exposed to DENV 3 months before are in orange. Naïve animals are in black. The frequency of the specific response to DENV and ZIKV antigens differs among cohorts. In all panels, animals exposed to DENV 12 months before ZIKV infection are in blue, while animals exposed to DENV 3 months before are in orange. Naïve animals are in black. All percentages shown are subtracted from the unstimulated background. (A) Analysis of CD4 T cell response to different stimuli before (upper panel) and 30 days after ZIKV infection (lower panel). (B) Analysis of CD8 T cell response to different stimuli before (upper panel) and 30 days after ZIKV infection (lower panel). Statistically significant differences among groups were calculated by two-way ANOVA using Dunnett's multiple comparisons test (*P<0.05 and ****P<0.0001). Colored stars represent a significantly different group, while colored lines represent the group that it is compared to. In all panels, animals exposed to DENV 12 months before ZIKV infection are in blue, while animals exposed to DENV 3 months before are in orange. Naïve animals are in black. Statistically significant differences among groups were calculated by two-way ANOVA using Tukey's, Sidak's and Dunnett's multiple comparisons tests (*P<0.05, **P<0.001 and ***P≤0.0001). Colored stars represent a significantly different group, while colored lines represent the group that it is compared to.
